Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD Study of RGB-02 vs Neulasta in Healthy Adults
NCT03146988Phase 1Completed
- Sponsor
- Gedeon Richter Plc
- Start
- Apr 2017
- Primary completion
- Sep 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RGB-02 in neutropenia (2 arms), sponsored by Gedeon Richter Plc. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Infinity at 67 days, Maximum Observed Serum Concentration at 67 days and 2 more. Started Apr 2017; status: completed.
02
Drugs
RGB-02
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT03146988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03146988.